[Listeria monocytogenes meningitis in the adult. Study of 10 cases].

P. Domingo Pedrol,J. Mancebo Cortés,L. Blanch Torra,P. Coll Figa,A. Net Castel,J. Nolla Panadés

Abstract:

What problem does this paper attempt to address?

Neurodegeneration with Brain Iron Accumulation Disorders and Retinal Neurovascular Structure

Elahe Amini,Mohammad Rohani,Alfonso Fasano,Zahra Azad,Shahnaz Miri,Seyed Amir Hassan Habibi,Maziar Emamikhah,Reza Mirshahi,Mohammad Taghi Joghataei,Zeinab Gholibeigian,Khalil Ghasemi Falavarjani

DOI: https://doi.org/10.1002/mds.29644

Abstract:Background: The unique neurovascular structure of the retina has provided an opportunity to observe brain pathology in many neurological disorders. However, such studies on neurodegeneration with brain iron accumulation (NBIA) disorders are lacking. Objectives: To investigate NBIA's neurological and ophthalmological manifestations. Methods: This cross-sectional study was conducted on genetically confirmed NBIA patients and an age-gender-matched control group. The thickness of retinal layers, central choroidal thickness (CCT), and capillary plexus densities were measured by spectral domain-optical coherence tomography (SD-OCT) and OCT angiography, respectively. The patients also underwent funduscopy, electroretinography (ERG), visual evoked potential (VEP), and neurological examination (Pantothenate-Kinase Associated Neurodegeneration-Disease Rating Scale [PKAN-DRS]). The generalized estimating equation model was used to consider inter-eye correlations. Results: Seventy-four patients' and 80 controls' eyes were analyzed. Patients had significantly decreased visual acuity, reduced inner or outer sectors of almost all evaluated layers, increased CCT, and decreased vessel densities, with abnormal VEP and ERG in 32.4% and 45.9%, respectively. There were correlations between visual acuity and temporal peripapillary nerve fiber layer (positive) and between PKAN-DRS score and disease duration (negative), and scotopic b-wave amplitudes (positive). When considering only the PKAN eyes, ONL was among the significantly decreased retinal layers, with no differences in retinal vessel densities. Evidence of pachychoroid was only seen in patients with Kufor Rakeb syndrome. Conclusion: Observing pathologic structural and functional neurovascular changes in NBIA patients may provide an opportunity to elucidate the underlying mechanisms and differential retinal biomarkers in NBIA subtypes in further investigations. © 2023 International Parkinson and Movement Disorder Society.
Metabolic impairments in neurodegeneration with brain iron accumulation

Agata Wydrych,Barbara Pakuła,Justyna Janikiewicz,Aneta M Dobosz,Patrycja Jakubek-Olszewska,Marta Skowrońska,Iwona Kurkowska-Jastrzębska,Maciej Cwyl,Mariola Popielarz,Paolo Pinton,Barbara Zavan,Agnieszka Dobrzyń,Magdalena Lebiedzińska-Arciszewska,Mariusz R Więckowski

DOI: https://doi.org/10.1016/j.bbabio.2024.149517

2024-10-02

Abstract:Neurodegeneration with brain iron accumulation (NBIA) is a broad, heterogeneous group of rare inherited diseases (1-3 patients/1,000,000 people) characterized by progressive symptoms associated with excessive abnormal iron deposition in the brain. Approximately 15,000-20,000 individuals worldwide are estimated to be affected by NBIA. NBIA is usually associated with slowly progressive pyramidal and extrapyramidal symptoms, axonal motor neuropathy, optic nerve atrophy, cognitive impairment and neuropsychiatric disorders. To date, eleven subtypes of NBIA have been described and the most common ones include pantothenate kinase-associated neurodegeneration (PKAN), PLA2G6-associated neurodegeneration (PLAN), mitochondrial membrane protein-associated neurodegeneration (MPAN) and beta-propeller protein-associated neurodegeneration (BPAN). We present a comprehensive overview of the evidence for disturbed cellular homeostasis and metabolic alterations in NBIA variants, with a careful focus on mitochondrial bioenergetics and lipid metabolism which drives a new perspective in understanding the course of this infrequent malady.
Early Neurological Deterioration in Patients with Acute Ischemic Stroke: a Prospective Multicenter Cohort Study

Hongbing Liu,Kai Liu,Ke Zhang,Ce Zong,Hongxun Yang,Yapeng Li,Shen Li,Xin Wang,Jiawei Zhao,Zongping Xia,Bo Song,Xuming Xu,Yuan Gao

DOI: https://doi.org/10.1177/17562864221147743

2023-01-01

Therapeutic Advances in Neurological Disorders

Abstract:Background: There is still no precise knowledge of the causes of progression in patients with acute ischemic stroke (AIS), and we are unable to predict patients at risk. Objective: To explore the frequency, predictive factors, and the prognosis of early neurological deterioration (END) in patients with AIS Methods: In this prospective multicenter observational study, we assessed patients with AIS admitted to 18 hospitals in Henan, China. We defined END as an increase of ⩾2 points in total National Institutes of Health Stroke Scale (NIHSS) score or ⩾1 point in the motor items of the NIHSS within 7 days after admission. Risk factors were analyzed using multivariate logistic regression models. Prognosis was evaluated using the modified Rankin Scale (mRS), with poor prognosis defined as mRS 3–6. Results: A total of 9114 patients with AIS within 24 h of symptom onset were enrolled in the study. END occurred in 1286 (14.1%) patients. The highest incidence (62.5%) of END occurred within 24 h after admission. After adjusting potential confounders, age, body mass index, waist–hip ratio, systolic blood pressure, baseline NIHSS, disabled at baseline, history of atrial fibrillation, diabetes mellitus, intracranial arterial stenosis, infarct location in the lenticulostriate artery area and cerebral watershed, neutrophils, lymphocytes, uric acid, and triglycerides were identified as independent predictors for END. END was significantly associated with poor prognosis at 90 days, and the adjusted OR was 1.74 (95% CI: 1.53–1.97). Conclusion: One in seven hospitalized patients with AIS may experience END within 24 h of onset. The highest incidence of END occurred within 24 h of admission and decreased steeply with time. Easily identifiable risk factors predict END and could help understand the causal mechanisms and thereby prevent END.
Mitochondrial Dysfunction, Oxidative Stress and Neuroinflammation in Neurodegeneration with Brain Iron Accumulation (NBIA)

Isabel Hinarejos,Candela Machuca,Paula Sancho,Carmen Espinós

DOI: https://doi.org/10.3390/antiox9101020

IF: 7.675

2020-10-20

Antioxidants

Abstract:The syndromes of neurodegeneration with brain iron accumulation (NBIA) encompass a group of invalidating and progressive rare diseases that share the abnormal accumulation of iron in the basal ganglia. The onset of NBIA disorders ranges from infancy to adulthood. Main clinical signs are related to extrapyramidal features (dystonia, parkinsonism and choreoathetosis), and neuropsychiatric abnormalities. Ten NBIA forms are widely accepted to be caused by mutations in the genes PANK2, PLA2G6, WDR45, C19ORF12, FA2H, ATP13A2, COASY, FTL1, CP, and DCAF17. Nonetheless, many patients remain without a conclusive genetic diagnosis, which shows that there must be additional as yet undiscovered NBIA genes. In line with this, isolated cases of known monogenic disorders, and also, new genetic diseases, which present with abnormal brain iron phenotypes compatible with NBIA, have been described. Several pathways are involved in NBIA syndromes: iron and lipid metabolism, mitochondrial dynamics, and autophagy. However, many neurodegenerative conditions share features such as mitochondrial dysfunction and oxidative stress, given the bioenergetics requirements of neurons. This review aims to describe the existing link between the classical ten NBIA forms by examining their connection with mitochondrial impairment as well as oxidative stress and neuroinflammation.

biochemistry & molecular biology,chemistry, medicinal,food science & technology
Altered Brain Iron Depositions from Aging to Parkinson's Disease and Alzheimer's Disease: A Quantitative Susceptibility Mapping Study

Xiaojun Guan,Cheng Zhou,Tao Guo,Jingjing Wu,Qingze Zeng,Kaicheng Li,Xiao Luo,Xueqin Bai,Haoting Wu,Ting Gao,Luyan Gu,Xiaocao Liu,Zhengye Cao,Jiaqi Wen,Jingwen Chen,Hongjiang Wei,Yuyao Zhang,Chunlei Liu,Zhe Song,Yaping Yan,Jiali Yan,Baorong Zhang,Xiaojun Xu,Minming Zhang

DOI: https://doi.org/10.1016/j.neuroimage.2022.119683

IF: 5.7

2022-01-01

NeuroImage

Abstract:Brain iron deposition is a promising marker for human brain health, providing insightful information for understanding aging as well as neurodegenerations, e.g., Parkinson's disease (PD) and Alzheimer's disease (AD). To comprehensively evaluate brain iron deposition along with aging, PD-related neurodegeneration, from prodromal PD (pPD) to clinical PD (cPD), and AD-related neurodegeneration, from mild cognitive impairment (MCI) to AD, a total of 726 participants from July 2013 to December 2020, including 100 young adults, 189 old adults, 184 pPD, 171 cPD, 31 MCI and 51 AD patients, were included. Quantitative susceptibility mapping data were acquired and used to quantify regional magnetic susceptibility, and the resulting spatial standard deviations were recorded. A general linear model was applied to perform the inter-group comparison. As a result, relative to young adults, old adults showed significantly higher iron deposition with higher spatial variation in all of the subcortical nuclei (p < 0.01). pPD showed a high spatial variation of iron distribution in the subcortical nuclei except for substantia nigra (SN); and iron deposition in SN and red nucleus (RN) were progressively increased from pPD to cPD (p < 0.01). AD showed significantly higher iron deposition in caudate and putamen with higher spatial variation compared with old adults, pPD and cPD (p < 0.01), and significant iron deposition in SN compared with old adults (p < 0.01). Also, linear regression models had significances in predicting motor score in pPD and cPD (Rmean = 0.443, Ppermutation = 0.001) and cognition score in MCI and AD (Rmean = 0.243, Ppermutation = 0.037). In conclusion, progressive iron deposition in the SN and RN may characterize PD-related neurodegeneration, namely aging to cPD through pPD. On the other hand, extreme iron deposition in the caudate and putamen may characterize AD-related neurodegeneration.
Transcatheter device closure of multiple defects in ruptured sinus of Valsalva aneurysm

A. Vamsidhar,D. Rajasekhar,V. Vanajakshamma

DOI: https://doi.org/10.1016/j.ihj.2015.06.025

2015-09-26

Indian Heart Journal

Abstract:
Effect of Ascertainment Bias on Estimates of Patient Mortality in Inherited Cardiac Diseases

Eline A Nannenberg,Ingrid A W van Rijsingen,Paul A van der Zwaag,Maarten P van den Berg,J Peter van Tintelen,Michael W T Tanck,Michael J Ackerman,Arthur A M Wilde,Imke Christiaans

DOI: https://doi.org/10.1161/CIRCGEN.117.001797

Abstract:Background: Accurate estimates of survival are indispensable for cardiologists, clinical geneticists, and genetic counselors dealing with families with an inherited cardiac disease. However, a bias towards a more severe disease with a worse outcome in the first publications may not accurately represent the actual survival forecast. We, therefore, evaluated the effect of ascertainment bias on survival in 3 different inherited cardiac diseases (idiopathic ventricular fibrillation, SCN5A overlap syndrome, and arrhythmogenic cardiomyopathy) caused by a founder mutation. Methods: We collected mortality data from mutation-positive subjects with either DPP6-associated idiopathic ventricular fibrillation, SCN5A overlap syndrome, and PLN-R14del-mediated arrhythmogenic cardiomyopathy >2 to 10 years of ongoing clinical/cascade genetic screening. Results: The median age of survival in DPP6 mutation-positive subjects increased from 44.6 years in the original cohort from 2008 (n=60; 95% CI, 36.8-52.4 years) to 68.2 years in the extended cohort from 2012 (n=235; 95% CI, 64.6-71.7 years; P<0.001). In the SCN5A overlap syndrome, survival increased from 56.1 years in 1999 (n=86; 95% CI, 48.0-64.2 years) to 69.7 years in 2009 (n=197; 95% CI, 61.3-78.2 years; P=0.049). In PLN-R14del positive patients, the median age of survival increased from 63.5 years in 2010 (n=89; 95% CI, 59.1-68.0 years) to 65.2 years in 2012 (n=370; 95% CI, 62.0-68.3 years; P=0.046). Conclusions: The median age of survival in 3 different inherited cardiac diseases with an established pathogenic substrate significantly increased once genetic testing and cascade screening extended, after the first publication that elucidated the discovery of the disease-susceptibility gene/mutation. This underscores the direct and negative influence of ascertainment bias on survival forecasts and the importance of ongoing clinical/genetic follow-up to establish the most accurate disease prognosis for genetically mediated heart diseases.
Mitochondrial iron deficiency triggers cytosolic iron overload in PKAN hiPS-derived astrocytes

Paolo Santambrogio,Anna Cozzi,Chiara Balestrucci,Maddalena Ripamonti,Valeria Berno,Eugenia Cammarota,Andrea Stefano Moro,Sonia Levi

DOI: https://doi.org/10.1038/s41419-024-06757-9

2024-05-26

Cell Death and Disease

Abstract:Disease models of neurodegeneration with brain iron accumulation (NBIA) offer the possibility to explore the relationship between iron dyshomeostasis and neurodegeneration. We analyzed hiPS-derived astrocytes from PANK2-associated neurodegeneration (PKAN), an NBIA disease characterized by progressive neurodegeneration and high iron accumulation in the globus pallidus. Previous data indicated that PKAN astrocytes exhibit alterations in iron metabolism, general impairment of constitutive endosomal trafficking, mitochondrial dysfunction and acquired neurotoxic features. Here, we performed a more in-depth analysis of the interactions between endocytic vesicles and mitochondria via superresolution microscopy experiments. A significantly lower number of transferrin-enriched vesicles were in contact with mitochondria in PKAN cells than in control cells, confirming the impaired intracellular fate of cargo endosomes. The investigation of cytosolic and mitochondrial iron parameters indicated that mitochondrial iron availability was substantially lower in PKAN cells compared to that in the controls. In addition, PKAN astrocytes exhibited defects in tubulin acetylation/phosphorylation, which might be responsible for unregulated vesicular dynamics and inappropriate iron delivery to mitochondria. Thus, the impairment of iron incorporation into these organelles seems to be the cause of cell iron delocalization, resulting in cytosolic iron overload and mitochondrial iron deficiency, triggering mitochondrial dysfunction. Overall, the data elucidate the mechanism of iron accumulation in CoA deficiency, highlighting the importance of mitochondrial iron deficiency in the pathogenesis of disease.

cell biology
Prediction of Individual Disease Progression Including Parameter Uncertainty in Rare Neurodegenerative Diseases: The Example of Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS)

Niels Hendrickx,France Mentré,Andreas Traschütz,Cynthia Gagnon,Rebecca Schüle,Matthis Synofzik,Emmanuelle Comets,ARCA Study Group,EVIDENCE-R. N. D. consortium

DOI: https://doi.org/10.1208/s12248-024-00925-7

2024-05-02

The AAPS Journal

Abstract:The aim of this study was to develop a model to predict individual subject disease trajectories including parameter uncertainty and accounting for missing data in rare neurological diseases, showcased by the ultra-rare disease Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS). We modelled the change in SARA (Scale for Assessment and Rating of Ataxia) score versus Time Since Onset of symptoms using non-linear mixed effect models for a population of 173 patients with ARSACS included in the prospective real-world multicenter Autosomal Recessive Cerebellar Ataxia (ARCA) registry. We used the Multivariate Imputation Chained Equation (MICE) algorithm to impute missing covariates, and a covariate selection procedure with a pooled p-value to account for the multiply imputed data sets. We then investigated the impact of covariates and population parameter uncertainty on the prediction of the individual trajectories up to 5 years after their last visit. A four-parameter logistic function was selected. Men were estimated to have a 25% lower SARA score at disease onset and a moderately higher maximum SARA score, and time to progression (T50) was estimated to be 35% lower in patients with age of onset over 15 years. The population disease progression rate started slowly at 0.1 points per year peaking to a maximum of 0.8 points per year (at 36.8 years since onset of symptoms). The prediction intervals for SARA scores 5 years after the last visit were large (median 7.4 points, Q1-Q3: 6.4–8.5); their size was mostly driven by individual parameter uncertainty and individual disease progression rate at that time.

pharmacology & pharmacy
The CamPaIGN Study of Parkinson's Disease: 10-Year Outlook in an Incident Population-Based Cohort

Caroline H. Williams-Gray,Sarah L. Mason,Jonathan R. Evans,Thomas Foltynie,Carol Brayne,Trevor W. Robbins,Roger A. Barker

DOI: https://doi.org/10.1136/jnnp-2013-305277

2013-01-01

Journal of Neurology Neurosurgery & Psychiatry

Abstract:BACKGROUND:Prognosis in Parkinson's disease (PD) remains poorly understood due to a lack of unbiased data on the natural history of treated PD. The CamPaIGN study has been the first to prospectively track disease evolution from diagnosis in an unselected population-representative incident cohort. We now report the 10-year follow-up data, focusing on three key irreversible milestones: postural instability (Hoehn and Yahr 3), dementia and death.METHODS:The cohort was collected between December 2000 and 2002. Those meeting diagnostic criteria (n=142) were followed-up until 1 January 2012. Clinical, neuropsychological and genetic testing were performed. Progression to key milestones was evaluated using Kaplan-Meier and Cox regression survival analyses.RESULTS:At 10 years, 55% had died, 68% had postural instability and 46% dementia. 23% had a good outcome at 10 years (surviving free of dementia/postural instability). Death rate was comparable with the UK population (standardised mortality ratio 1.29 (0.97-1.61)). Death certificates indicated PD was a substantial contributor in only 20%, with pneumonia being the commonest cause of death. Age, non-tremor-dominant motor phenotype and comorbidity predicted earlier postural instability. Baseline predictors of dementia were age, motor impairment, 'posterior-cortical' cognitive deficits and MAPT genotype.CONCLUSIONS:(1) outlook in PD is heterogeneous, with most dying or developing dementia or postural instability by 10 years from diagnosis, but a quarter still doing well, with preserved mobility and intact cognition; (2) death is not directly related to PD in the majority; (3) baseline clinical and genetic variables are predictive of outcome and may be helpful in selecting patients for clinical trials.
Median Nerve-Neurophysiological Index Correlates With the Survival of Patients With Amyotrophic Lateral Sclerosis

Liu-Qing Xu,Wei Hu,Qi-Fu Guo,Lu-Lu Lai,Guo-Rong Xu,Wan-Jin Chen,Ning Wang,Qi-Jie Zhang

DOI: https://doi.org/10.3389/fneur.2020.570227

IF: 3.4

2020-10-22

Frontiers in Neurology

Abstract:Objective: This study aims to explore the association between median nerve-neurophysiological index (NI) and survival of patients with amyotrophic lateral sclerosis (ALS).Methods: A retrospective case series with a prospective follow-up study was performed in 238 patients with ALS. Their clinical profiles and NI were recorded. Kaplan-Meier curves and Cox regression were adopted to perform survival analysis.Results: The median survival time of all ALS cases was 33.0 months. Multivariate analysis showed that older age of onset, shorter diagnostic delay, higher ΔALSFRS-R, and faster progression {NI ≤ 2.15; hazard ratio [HR] = 1.543 [95% confidence interval (CI), 1.136–2.094]} were associated with short survival. NI was correlated with ALSFRS-R at baseline (rs = 0.3153; p < 0.0001) and ALSFRS-R at different time points of follow-up (rs = 0.5127; p < 0.0001). The higher NI slope of decline (> 0.25) showed shorter survival compared with the lower group (≤ 0.25; 34.0 vs. 52.0 months; p = 0.0003). A predictive model was constructed based on the age of onset, diagnostic delay, median nerve NI, and ΔALSFRS-R. The higher predictive score (> 14) showed significantly shorter survival compared with the lower group (≤ 14; HR = 3.907, 95% CI, 2.857–5.342).Conclusion: Median nerve NI and its slope of decline were predictive of survival of ALS.

neurosciences,clinical neurology
Predicting disability and mortality in CV2/CRMP5‐IgG associated paraneoplastic neurologic disorders

Sanem P. Uysal,Yadi Li,Nicolas R. Thompson,Alex Milinovich,Justin R. Abbatemarco,Jeffrey A. Cohen,Devon S. Conway,Daniel Ontaneda,John A. Morren,Amy Kunchok

DOI: https://doi.org/10.1002/acn3.51991

IF: 5.43

2024-01-24

Annals of Clinical and Translational Neurology

Abstract:Background We aimed to investigate the prognostic factors associated with clinical outcomes in CV2/Collapsin response‐mediator protein 5 (CRMP5)‐IgG paraneoplastic neurologic disorders (PND). Methods This is a retrospective study of patients with CV2/CRMP5‐IgG PND evaluated between 2002–2022. We examined the association of clinical variables (including age, clinical phenotype [autoimmune encephalopathy, myelopathy, polyneuropathy/radiculopathy, MG, cerebellar ataxia, chorea, optic neuropathy], cancer) with three clinical outcomes (wheelchair dependence, modified Rankin Scale [mRS], mortality) using univariate logistic regression and Cox proportional hazards modeling. Kaplan–Meier estimates were used to determine the probability of survival. Results Twenty‐seven patients (56% female) with CV2/CRMP5‐IgG PND were identified with a median follow‐up of 54 months (IQR = 11–102). An underlying tumor was identified in 15 patients (56%) including small cell lung cancer (SCLC) (8, [53%]), thymoma (4, [27%]), and other histologies (3, [20%]). At last follow‐up, 10 patients (37%) needed a wheelchair for mobility and this outcome was associated with myelopathy (HR = 7.57, 95% CI = 1.87–30.64, P = 0.005). Moderate–severe mRS = 3–5 was associated with CNS involvement (encephalopathy, myelopathy, or cerebellar ataxia) (OR = 7.00, 95% CI = 1.18–41.36, P = 0.032). The probability of survival 4 years after symptom onset was 66%. Among cancer subtypes, SCLC (HR = 18.18, 95% CI = 3.55–93.04, P

neurosciences,clinical neurology
Bilateral subthalamic nucleus stimulation in the treatment of neurodegeneration with brain iron accumulation type 1.

Ming Ge,Kai Zhang,Yu Ma,Fan-gang Meng,Wen-han Hu,An-chao Yang,Jian-guo Zhang

DOI: https://doi.org/10.1159/000323374

IF: 1.643

2011-01-01

Stereotactic and Functional Neurosurgery

Abstract:Background: Neurodegeneration with brain iron accumulation type 1 (NBIA1), previously called Hallervorden-Spatz disease, is a rare neurodegenerative condition with abnormal brain iron accumulation. There have been some reports of deep brain stimulation (DBS) in the treatment of NBIA1. However, the target was usually the globus pallidus internus or thalamus. Objectives/Methods: We present a case of NBIA1 in a 16-year-old male who was treated with bilateral subthalamic nucleus (STN)-DBS and explored its efficacy in the treatment of NBIA1. The patient presented with severe generalized dystonia and marked dysarthria and had previously had unsuccessful ablation surgery. MRI confirmed the diagnosis of NBIA1. Results: He had significant improvement postoperatively, and the benefit of surgery was maintained for 3 years during follow-up. Burke-Fahn-Marsden Dystonia Rating Scale score was 114/120 preoperatively, and dropped to 60/120 at 14 days, 35/120 at 1 month, 28/120 at 3 months, 14/120 at 1 year and 18/120 at 3 years postoperatively. Conclusions: Our results suggest that bilateral STN-DBS might be considered as an effective treatment for selective NBIA1 patients. Copyright (C) 2011 S. Karger AG, Basel
ANALYSIS OF SURVIVAL TIME AND FUNCTIONAL PROGRESSION IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS: A LONGITUDINAL STUDY

Lariza Maria da Costa,Natália Lopes Cardoso,Karen de Medeiros Pondofe,Guilherme Augusto De Freitas Fregonezi,Vanessa Regiane Resqueti Fregonezi,Rayane Grayce da Silva Vieira

DOI: https://doi.org/10.1016/j.bjpt.2024.100836

IF: 4.762

2024-04-01

Brazilian Journal of Physical Therapy

Abstract:Background Amyotrophic lateral sclerosis (ALS) is a disease that causes progressive degeneration of neurons present in the spinal cord and cerebral cortex. It is a disease with a progressive course, with worsening disability and death 3 to 5 years after diagnosis. However, some patients seem to have a slower progression, while others maintain a rapid progression, which may influence the clinical course of the disease and accelerate death. Objectives To evaluate the survival time of patients with ALS, according to the progression of the disease in rapid or slow, and to compare the level of functionality between two evaluations. Methods A longitudinal case series study that followed patients with a confirmed diagnosis of ALS from August 2018 to February 2022. Data were collected from medical records of periodic evaluations, in which pulmonary function tests were performed and the ALS Functional Assessment Scale (ALSFRS-r) was applied. From the values obtained in the scale, the progression rate was calculated, where the patients were divided into slow or rapid progression and followed for 3.5 years for statistical analysis of survival, later performed by the Kaplan-Meyer test. The results of the scores of the first and second evaluation of each patient were compared using the paired t-test. Results 11 patients were followed, 7 with rapid progression (63%) and 4 slow (37%) with a mean age of 61.64 years and forced vital capacity (FVC): 62.2 (38.7-85.7)%pred. In the functionality evaluation, it was observed that there was a significant reduction (p<0.01) in the total scale score compared to the first evaluation. The survival percentage was 0%, where all patients died at the end of the study, but the median survival of the slow progression group from the first evaluation until the final outcome was 46 months, while the rapid progression group was 28 months, with no significant difference between the survival curves (HR = 0.42; CI 0.12 - 1.48). Conclusion The present study was able to demonstrate that after the second evaluation ALS patients may have significant losses of functionality by the decline of the ALSFRS-r functional score. Also, it can determine the evolution of the disease and assist in identifying the speed of progression of the pathology. Implications Regular use of the ALS functional assessment scale and calculation of the rate of progression in the outpatient clinical setting becomes essential to chart a better short- and long-term prognosis and follow-up of the disease.

rehabilitation,orthopedics
Determination of Health Concepts in β-Propeller Protein–Associated Neurodegeneration

Emma Kotes,Francesco Gavazzi,Sarah Woidill,Anjana Sevagamoorthy,Eric Yang,Vanessa Smith,Holly Dubbs,Samuel R. Pierce,Kristy Pucci,Joseph Vithayathil,Nivedita Thakur,Laura A. Adang

DOI: https://doi.org/10.1177/08830738241283932

2024-10-10

Journal of Child Neurology

Abstract:Journal of Child Neurology, Ahead of Print. β-Propeller protein–associated neurodegeneration (BPAN) is a rare, X-linked condition caused by pathogenic variants in the WDR45 gene that result in a defect of autophagy. Classified as a disorder of neurodegeneration with brain iron accumulation, β-propeller protein–associated neurodegeneration is associated with severe neurologic impairments. With the anticipation of future therapeutic trials, this project characterizes the family's perspective of the impact of disease and defines Health Concepts (HC).Children with a molecularly confirmed diagnosis of β-propeller protein–associated neurodegeneration were enrolled in a prospective natural history study. We administered the Vineland Adaptive Behavior Scales–Third Edition and provided health-related quality of life questionnaires to 42 caregivers. Questionnaires included Pediatric Quality of Life Inventory–Generic Core and Pediatric Quality of Life Inventory–Family Impact modules, Caregiver Priorities and Child Health Index of Life with Disabilities, and Caregiver TBI-CareQoL.The Vineland Adaptive Behavior Scales–Third Edition (n = 42) captured the family's perspective that communication was more affected compared with socialization, activities of daily living (ADL), and motor skills (P < .0001, P < .0001, P = .0053, respectively). Similarly, on the Caregiver Priorities and Child Health Index of Life with Disabilities (n = 26), Pediatric Quality of Life Inventory–Generic Core (n = 27), CareQol (n = 26), and Pediatric Quality of Life Inventory–Family Impact (n = 27), communication abilities, as well as social functioning and activities of daily living, were noted to be most impacted.Through the use of standardized surveys and outcome assessments, we establish the effects of β-propeller protein–associated neurodegeneration on caregiver quality of life. Key health concepts identified by families included overall health, comfort, and communication. The identified HC will inform the future identification of concept of interest and selection of appropriate clinical outcome assessments through the administration of patient-reported outcomes.

pediatrics,clinical neurology
Multimodal, Longitudinal Profiling of SCA1 Identifies Predictors of Disease Severity and Progression

Teije H van Prooije,Kirsten C J Kapteijns,Jack J A van Asten,Joanna IntHout,Marcel M Verbeek,Tom W J Scheenen,Bart P van de Warrenburg

DOI: https://doi.org/10.1002/ana.27032

Abstract:Objectives: Spinocerebellar ataxia type 1 (SCA1) is a rare autosomal dominant neurodegenerative disease. Objective surrogate markers sensitive to detect changes in disease severity are needed to reduce sample sizes in interventional trials and identification of predictors of faster disease progression would facilitate patient selection, enrichment, or stratification in such trials. Methods: We performed a prospective 1-year longitudinal, multimodal study in 34 ataxic SCA1 individuals and 21 healthy controls. We collected clinical, patient-reported outcomes, biochemical and magnetic resonance (MR) biomarkers at baseline and after 1 year. We determined 1-year progression and evaluated the potential predictive value of several baseline markers on 1-year disease progression. Results: At baseline, multiple structural and spectroscopic MR markers in pons and cerebellum differentiated SCA1 from healthy controls and correlated with disease severity. Plasma and cerebrospinal fluid (CSF) neurofilament light (NfL) chain and CSF glial fibrillary acidic protein (GFAP) were elevated in SCA1. In longitudinal analysis, total brainstem and pontine volume change, inventory of non-ataxia signs (INAS) count, and SCA functional index (SCAFI) showed larger responsiveness compared to the Scale for Assessment and Rating of Ataxia (SARA). Longer disease duration, longer non-expanded CAG repeat length, and higher disease burden were associated with faster SARA increase after 1-year in the SCA1 group. Similarly, lower baseline brainstem, pontine, and cerebellar volumes, as well as lower levels of N-acetylaspartate and glutamate in the cerebellar white matter, were also associated with faster SARA increase. Interpretation: Our results guide the selection of the most sensitive measures of disease progression in SCA1 and have identified features associated with accelerated progression that could inform the design of clinical trials. ANN NEUROL 2024;96:774-787.
Iron Dyshomeostasis in Neurodegeneration with Brain Iron Accumulation (NBIA): Is It the Cause or the Effect?

Francesco Agostini,Bibiana Sgalletta,Marco Bisaglia

DOI: https://doi.org/10.3390/cells13161376

IF: 6

2024-08-20

Cells

Abstract:Iron is an essential metal ion implicated in several cellular processes. However, the reactive nature of iron renders this metal ion potentially dangerous for cells, and its levels need to be tightly controlled. Alterations in the intracellular concentration of iron are associated with different neuropathological conditions, including neurodegeneration with brain iron accumulation (NBIA). As the name suggests, NBIA encompasses a class of rare and still poorly investigated neurodegenerative disorders characterized by an abnormal accumulation of iron in the brain. NBIA is mostly a genetic pathology, and to date, 10 genes have been linked to familial forms of NBIA. In the present review, after the description of the principal mechanisms implicated in iron homeostasis, we summarize the research data concerning the pathological mechanisms underlying the genetic forms of NBIA and discuss the potential involvement of iron in such processes. The picture that emerges is that, while iron overload can contribute to the pathogenesis of NBIA, it does not seem to be the causal factor in most forms of the pathology. The onset of these pathologies is rather caused by a combination of processes involving the interplay between lipid metabolism, mitochondrial functions, and autophagic activity, eventually leading to iron dyshomeostasis.

cell biology
Study of Biochemical Predictors of Early Neurological Deterioration in Ischemic Stroke in a Tertiary Care Hospital

Manasi Harale,Arun Oommen,Ahsan Faruqi,Mayank Mundada,Raju Hansini Reddy,Tushar Pancholi,Bhavya Yammanuru,Sree Vidya Yekkaluru,Abishak Gupta,Shivraj Patil

DOI: https://doi.org/10.7759/cureus.68183

2024-08-30

Cureus

Abstract:Background and objective Early neurological deterioration (END) following acute ischemic stroke (AIS) poses a significant clinical challenge, often leading to increased disability and mortality. This study aimed to investigate the association between specific biomarkers (lactate dehydrogenase (LDH), ferritin, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), homocysteine) and the occurrence of END in ischemic stroke patients in a tertiary care hospital. Materials and methods A cross-sectional hospital-based study was conducted at Dr. D. Y. Patil Medical College and Hospital, Pune, from July 2022 to April 2024. Patients aged 18 and above with confirmed ischemic stroke were included, while those with hemorrhagic stroke, intracranial tumors, mass effect with midline shift, or extensive cerebral edema were excluded. Upon admission, patients were assessed using the National Institutes of Health Stroke Scale (NIHSS) and monitored daily for seven days. Biomarkers, including LDH, ferritin, ESR, CRP, and homocysteine, were measured, and patients were categorized into those with END and without END. Statistical analysis was performed using IBM SPSS Statistics for Windows, Version 20 (Released 2011; IBM Corp., Armonk, New York). Results Out of 100 patients, 12% experienced END. The mean age of patients with END was 53.50 ± 11.20 years, compared to 53.62 ± 11.74 years in those without END (p = 0.790). Males constituted 91.7% of the END group and 73.9% of the non-END group (p = 0.284). A significant association was found between END and alcohol use (41.7% in END vs. 12.5% in non-END, p = 0.010) and tobacco use (41.7% in END vs. 11.4% in non-END, p = 0.010). The mean NIHSS scores were significantly higher in the END group on day 1 (11.58 ± 3.06 vs. 7.69 ± 3.98, p = 0.002) and on day 3 (13.92 ± 3.15 vs. 6.00 ± 3.65, p = 0.001). Biomarker analysis showed a significant difference in the mean vitamin B12 levels between END and non-END groups (93.17 ± 48.58 vs. 183.45 ± 349.33, p = 0.025). Conclusion Our study identified significant predictors of END in ischemic stroke patients, including alcohol and tobacco use, higher initial NIHSS scores, and elevated levels of LDH, ferritin, ESR, CRP, and homocysteine, along with low vitamin B12 levels. These findings highlight the importance of routine biochemical assessments and personalized treatment plans in managing AIS, emphasizing lifestyle changes and nutritional support to improve outcomes. Limitations include the single-center design, small sample size, and lack of long-term follow-up data. Future research should validate these findings in larger, multicenter studies and explore their long-term impact on stroke recovery.
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts.

Tien Dam,Gennaro Pagano,Michael C. Brumm,Caroline Gochanour,Kathleen L. Poston,Daniel Weintraub,Lana M. Chahine,Christopher S. Coffey,Caroline M. Tanner,Catherine M. Kopil,Yuge Xiao,Sohini Chowdhury,Luis Concha-Marambio,Peter DiBiaso,Tatiana Foroud,Mark Frasier,Danna Jennings,Karl Kieburtz,Kalpana Merchant,Brit Mollenhauer,Thomas J. Montine,Kelly Nudelman,John Seibyl,Todd Sherer,Andrew Singleton,Diane Stephenson,Matthew Stern,Claudio Soto,Eduardo Tolosa,Andrew Siderowf,Billy Dunn,Tanya Simuni,Kenneth Marek,and the Parkinson's Progression Markers Initiative

DOI: https://doi.org/10.1101/2024.02.14.24302818

2024-09-10

Abstract:The Neuronal alpha-Synuclein Disease (NSD) biological definition and Integrated Staging System (NSD-ISS) provide a research framework to identify individuals with Lewy body pathology and stage them based on underlying biology and increasing degree of functional impairment. Utilizing data from the PPMI, PASADENA and SPARK studies, we developed and applied biologic and clinical data-informed definitions for the NSD-ISS across the disease continuum. Individuals enrolled as Parkinson's disease, Prodromal, or Healthy Controls were defined and staged based on biological, clinical, and functional anchors at baseline. Across the three studies 1,741 participants had SAA data and of these 1,030 (59%) were S+ consistent with NSD. Among sporadic PD, 683/736 (93%) were NSD, and the distribution for Stages 2B, 3, and 4 was 25%, 63%, and 9%, respectively. Median (95% CI) time to developing a clinically meaningful outcome was 8.3 (6.2, 10.1), 5.9 (4.1, 6.0), and 2.4 (1.0, 4.0) years for baseline stage 2B, 3, and 4, respectively. We propose pilot biologic and clinical anchors for NSD-ISS. Our results highlight the baseline heterogeneity of individuals currently defined as early PD. Baseline stage predicts time to progression to clinically meaningful milestones. Further research on validation of the anchors in longitudinal cohorts is necessary.
Natural history and genotype-phenotype correlation of pantothenate kinase-associated neurodegeneration

Xuting Chang,Jie Zhang,Yuwu Jiang,Jingmin Wang,Ye Wu

DOI: https://doi.org/10.1111/cns.13294

2020-01-01

CNS Neuroscience & Therapeutics

Abstract:Aims To investigate the natural history and genotype-phenotype correlation of pantothenate kinase-associated neurodegeneration. Methods We collected data of patients with PKAN by searching from available publications in English and Chinese. Patients diagnosed in our center (Peking University First Hospital) were also included. The difference in natural history and genotype between early-onset (<10 year of age at onset) and late-onset patients (>= 10 year of age at onset) with PKAN was compared. Results A total of 248 patients were included. The median age at onset was 3.0 years in the early-onset group and 18.0 years in the late-onset group. Dystonia in lower limbs was the most common initial symptom in both groups. In the early-onset group, the median interval between the disease onset and occurrence of oromandibular dystonia, generalized dystonia, loss of independent ambulance was 6.0 years, 5.0 years, and 5.0 years. The corresponding values in late-onset group were 1.0 year, 4.0 years, and 6.0 years. About 20.0% died at median age of 12.5 years and 9.5 years after the onset in early-onset group. About 2.0% of the late-onset patients died during the follow-up. A total of 176 mutations were identified. Patients carrying two null alleles in PANK2 showed significantly earlier age of disease onset and progressed more rapidly to loss of independent ambulance. Conclusions This study provided a comprehensive review on the natural history and genotype of 248 patients with PKAN. The results will serve as a historical control data for future clinical trial on PKAN.

[Listeria monocytogenes meningitis in the adult. Study of 10 cases].

Neurodegeneration with Brain Iron Accumulation Disorders and Retinal Neurovascular Structure

Metabolic impairments in neurodegeneration with brain iron accumulation

Early Neurological Deterioration in Patients with Acute Ischemic Stroke: a Prospective Multicenter Cohort Study

Mitochondrial Dysfunction, Oxidative Stress and Neuroinflammation in Neurodegeneration with Brain Iron Accumulation (NBIA)

Altered Brain Iron Depositions from Aging to Parkinson's Disease and Alzheimer's Disease: A Quantitative Susceptibility Mapping Study

Transcatheter device closure of multiple defects in ruptured sinus of Valsalva aneurysm

Effect of Ascertainment Bias on Estimates of Patient Mortality in Inherited Cardiac Diseases

Mitochondrial iron deficiency triggers cytosolic iron overload in PKAN hiPS-derived astrocytes

Prediction of Individual Disease Progression Including Parameter Uncertainty in Rare Neurodegenerative Diseases: The Example of Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS)

The CamPaIGN Study of Parkinson's Disease: 10-Year Outlook in an Incident Population-Based Cohort

Median Nerve-Neurophysiological Index Correlates With the Survival of Patients With Amyotrophic Lateral Sclerosis

Predicting disability and mortality in CV2/CRMP5‐IgG associated paraneoplastic neurologic disorders

Bilateral subthalamic nucleus stimulation in the treatment of neurodegeneration with brain iron accumulation type 1.

ANALYSIS OF SURVIVAL TIME AND FUNCTIONAL PROGRESSION IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS: A LONGITUDINAL STUDY

Determination of Health Concepts in β-Propeller Protein–Associated Neurodegeneration

Multimodal, Longitudinal Profiling of SCA1 Identifies Predictors of Disease Severity and Progression

Iron Dyshomeostasis in Neurodegeneration with Brain Iron Accumulation (NBIA): Is It the Cause or the Effect?

Study of Biochemical Predictors of Early Neurological Deterioration in Ischemic Stroke in a Tertiary Care Hospital

Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts.

Natural history and genotype-phenotype correlation of pantothenate kinase-associated neurodegeneration